Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn’s Disease
Laurent Peyrin‐Biroulet, J. Casey Chapman, Jean‐Frédéric Colombel, et al.
New England Journal of Medicine (2024) Vol. 391, Iss. 3, pp. 213-223
Closed Access | Times Cited: 31

Showing 1-25 of 31 citing articles:

Understanding the therapeutic toolkit for inflammatory bowel disease
Sophie Vieujean, Vipul Jairath, Laurent Peyrin‐Biroulet, et al.
Nature Reviews Gastroenterology & Hepatology (2025)
Closed Access | Times Cited: 2
Recent advances in epidemiology, pathogenesis, diagnosis, and treatment of inflammatory bowel disease: Insights from the past two years
Jian Wan, Jiaming Zhou, Zhuo Wang, et al.
Chinese Medical Journal (2025)
Open Access | Times Cited: 1
Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study
Marc Ferrante, Geert R. D’Haens, Vipul Jairath, et al.
The Lancet (2024) Vol. 404, Iss. 10470, pp. 2423-2436
Closed Access | Times Cited: 9
Anwendung fortgeschrittener Therapien bei chronisch-entzündlichen Darmerkrankungen
Benjamin Misselwitz, Sebastian Zeißig, Stefan Schreiber, et al.
Deleted Journal (2025)
Open Access
Therapie des schweren Schubs bei Morbus Crohn und Colitis ulcerosa
Andreas Stallmach, Johannes Stallhofer, Carsten Schmidt, et al.
Deleted Journal (2025)
Closed Access
Risankizumab bei M. Crohn überlegen

Zeitschrift für Gastroenterologie (2025) Vol. 63, Iss. 01, pp. 19-20
Closed Access
Guselkumab: A New Therapeutic Option for the Treatment of Moderately to Severely Active Ulcerative Colitis
Shubha Bhat, David Choi
Annals of Pharmacotherapy (2025)
Closed Access
Landscape of anti-IL-23 therapy in inflammatory bowel disease: recent advances
Michael Colwill, Jennifer Clough, Samantha Baillie, et al.
Frontline Gastroenterology (2025), pp. flgastro-102830
Closed Access
Risankizumab for Ulcerative Colitis
Li Peng
JAMA (2025)
Closed Access
Drug Development in Inflammatory Bowel Diseases: What Is Next?
Lorenzo Petronio, Arianna Dal Buono, Roberto Gabbiadini, et al.
Pharmaceuticals (2025) Vol. 18, Iss. 2, pp. 190-190
Open Access
The VIVID-1 study: A novel methodological approach provides further evidence of efficacy of selective IL-23 inhibition in Crohn’s disease
Maria Cappello, Ciro Celsa
Med (2025) Vol. 6, Iss. 2, pp. 100572-100572
Closed Access
Positionspapier der Gesellschaft für Pädiatrische Gastroenterologie und Ernährung (GPGE) zum zulassungsüberschreitenden Gebrauch von für Erwachsene mit CED zugelassenen Biologika und Signalinhibitoren bei Kindern und Jugendlichen
Jan Däbritz, Martin Claßen, K. Krohn, et al.
Zeitschrift für Gastroenterologie (2025)
Open Access
First-line anti-TNF agents, ustekinumab and vedolizumab perform similarly in Crohn’ disease, but not in ulcerative colitis
Eva Supovec, Jurij Hanžel, Gregor Novak, et al.
European Journal of Gastroenterology & Hepatology (2025)
Closed Access
What is first-line and what is second-line therapy in adult patients with moderate to severe Crohn’s disease?
Remo Panaccione
Journal of the Canadian Association of Gastroenterology (2025) Vol. 8, Iss. Supplement_2, pp. S1-S5
Open Access
The Expanding Therapeutic Potential of Deucravacitinib Beyond Psoriasis: A Narrative Review
Chul Hwan Bang, Chul Jong Park, Yoon‐Seob Kim
Journal of Clinical Medicine (2025) Vol. 14, Iss. 5, pp. 1745-1745
Open Access
Treatment sequencing in inflammatory bowel disease : towards clinical precision medicine
Léa Sequier, Bénédicte Caron, Sailish Honap, et al.
Best Practice & Research Clinical Gastroenterology (2025), pp. 101994-101994
Closed Access
Risk factors for humanized IgG1 monoclonal antibody in the treatment of Crohn's disease: pharmacovigilance of the FDA adverse event reporting system (FAERS)
Jiangchuan Xie, Chun Tao, Linli Xie, et al.
Research Square (Research Square) (2025)
Closed Access
IL23p19 therapies for moderately-to-severely active ulcerative colitis
Newaz Shubidito Ahmed, Christopher Ma
Expert Opinion on Biological Therapy (2025)
Closed Access
Guselkumab in moderately to severely active ulcerative colitis: Another interleukin-23p19 subunit inhibitor or more?
Ambrogio Orlando, Fabio Salvatore Macaluso
Med (2025) Vol. 6, Iss. 3, pp. 100605-100605
Closed Access
Treatment trajectories and outcomes in inflammatory bowel disease: a tertiary single-centre experience
Kim Wagner, Tanja M. Müller, Francesco Vitali, et al.
Therapeutic Advances in Gastroenterology (2024) Vol. 17
Open Access | Times Cited: 2
Interpreting modern randomized controlled trials of medical therapy in inflammatory bowel disease
Christopher Ma, Vipul Jairath, Brian G. Feagan, et al.
Nature Reviews Gastroenterology & Hepatology (2024) Vol. 21, Iss. 11, pp. 792-808
Closed Access | Times Cited: 1
Interleukin-21 and Interleukin-23 levels in familial Mediterranean Fever before and after treatment: the role of cytokines in disease pathogenesis
Mutlu Hızal, Abdurrahman Tufan, Rıdvan Mercan, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 1
Translational characterization of immune pathways in inflammatory bowel disease: insights for targeted treatments
Sabrina Nicolò, Ilaria Faggiani, C Errico, et al.
Expert Review of Clinical Immunology (2024), pp. 1-18
Closed Access | Times Cited: 1
Mirikizumab for the treatment of chronic antibiotic-refractory pouchitis
Johannes Reiner, Anne‐Sophie Becker, A Huth, et al.
Zeitschrift für Gastroenterologie (2024)
Closed Access
New treatments in inflammatory bowel disease � A thrilling time ahead
Fernando Gomollón
Revista Española de Enfermedades Digestivas (2024) Vol. 116
Open Access
Page 1 - Next Page

Scroll to top